Aldeyra Therapeutics (ALDX) Profit After Tax (2013 - 2026)

Aldeyra Therapeutics (ALDX) has 14 years of Profit After Tax data on file, last reported at -$3.5 million in Q1 2026.

• Quarterly Profit After Tax rose 65.23% year-over-year to -$3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$27.4 million (up 52.6% YoY) and the FY2025 annual result came in at -$33.8 million, up 39.45% from the prior year.
• Profit After Tax advanced to -$3.5 million in Q1 2026, from -$6.5 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$3.5 million in Q1 2026 to a low of -$17.8 million in Q2 2022.
• A 5-year average of -$11.3 million and a median of -$9.9 million in 2025 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2024 — Profit After Tax tumbled 233.63% — and 2026, when it surged 65.23%.
• Tracing ALDX's Profit After Tax over 5 years: stood at -$12.9 million in 2022, then soared by 63.09% to -$4.8 million in 2023, then plunged by 233.63% to -$15.9 million in 2024, then jumped by 59.25% to -$6.5 million in 2025, then soared by 46.57% to -$3.5 million in 2026.
• The last three Profit After Tax figures came in at -$3.5 million (Q1 2026), -$6.5 million (Q4 2025), and -$7.7 million (Q3 2025), per Business Quant data.